BACKGROUND: The aim of our work is to assess the clinical outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC) in HIV-coinfected patients. This is a multicenter study involving three Italian transplant centers in northern Italy: University of Modena, University of Bologna, and University of Udine. PATIENTS AND METHODS: We compared 30 HIV-positive patients affected by HCC who underwent LT with 125 HIV-uninfected patients who received the same treatment from September 2004 to June 2009. At listing, there were no differences between HIV-infected and -uninfected patients regarding HCC features. Patients outside the University of California, San Francisco criteria (UCSF) were considered eligible for LT if a down-staging program permitted a reduction of tumor burden. RESULTS: HIV-infected patients were younger, they were more frequently anti-HCV positive, and a higher number of HIV-infected patients presented a coinfection HBV-HCV. Pre-LT treatments (liver resection and or locoregional treatments) were similar between the two groups. Histological characteristics of the tumor were similar in patients with and without HIV infection. No differences were observed in terms of overall survival and HCC recurrence rates. CONCLUSION: LT for HCC is a feasible procedure and the presence of HIV does not particularly affect the post-LT outcome.
BACKGROUND: The aim of our work is to assess the clinical outcomes of liver transplantation (LT) for hepatocellular carcinoma (HCC) in HIV-coinfectedpatients. This is a multicenter study involving three Italian transplant centers in northern Italy: University of Modena, University of Bologna, and University of Udine. PATIENTS AND METHODS: We compared 30 HIV-positive patients affected by HCC who underwent LT with 125 HIV-uninfectedpatients who received the same treatment from September 2004 to June 2009. At listing, there were no differences between HIV-infected and -uninfected patients regarding HCC features. Patients outside the University of California, San Francisco criteria (UCSF) were considered eligible for LT if a down-staging program permitted a reduction of tumor burden. RESULTS:HIV-infectedpatients were younger, they were more frequently anti-HCV positive, and a higher number of HIV-infectedpatients presented a coinfection HBV-HCV. Pre-LT treatments (liver resection and or locoregional treatments) were similar between the two groups. Histological characteristics of the tumor were similar in patients with and without HIV infection. No differences were observed in terms of overall survival and HCC recurrence rates. CONCLUSION: LT for HCC is a feasible procedure and the presence of HIV does not particularly affect the post-LT outcome.
Authors: Fabrizio Di Benedetto; Giuseppe Tarantino; Roberto Montalti; Giuseppe D'Amico; Stefania Cocchi; Giorgio E Gerunda Journal: Hepatology Date: 2011-05 Impact factor: 17.425
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: F Di Benedetto; S Di Sandro; N De Ruvo; M Berretta; R Montalti; G P Guerrini; R Ballarin; M G De Blasiis; M Spaggiari; N Smerieri; R M Iemmolo; G Guaraldi; G E Gerunda Journal: Transplant Proc Date: 2008 Jul-Aug Impact factor: 1.066
Authors: A Corallini; G Altavilla; L Pozzi; F Bignozzi; M Negrini; P Rimessi; F Gualandi; G Barbanti-Brodano Journal: Cancer Res Date: 1993-11-15 Impact factor: 12.701
Authors: Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts Journal: Hepatology Date: 2008-09 Impact factor: 17.425
Authors: V Martel-Laferrière; A Michel; S Schaefer; S Bindal; K Bichoupan; A D Branch; S Huprikar; T D Schiano; P V Perumalswami Journal: Transpl Infect Dis Date: 2015-06-15 Impact factor: 2.228
Authors: Umberto Baccarani; Elda Righi; Gian Luigi Adani; Dario Lorenzin; Alberto Pasqualucci; Matteo Bassetti; Andrea Risaliti Journal: World J Gastroenterol Date: 2014-05-14 Impact factor: 5.742
Authors: Massimiliano Berretta; Luca Rinaldi; Fabrizio Di Benedetto; Arben Lleshi; Vallì De Re; Gaetano Facchini; Paolo De Paoli; Raffaele Di Francia Journal: Front Pharmacol Date: 2016-11-09 Impact factor: 5.810